SCHEMBL1020282

SCHEMBL1020282

COc1ccc(S(=O)(=O)NCC(C)Nc2nc(Cc3ccccc3OC)ns2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
ALDH1A1 P00352 5/20 0.41
LMNA P02545 4/20 0.41
POLB P06746 2/20 0.41
TSHR P16473 2/20 0.41
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR7 P34969 2/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 2/20 0.39
NPC1 O15118 1/20 0.39
MEN1 O00255 1/20 0.39
HTR1A P08908 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTT P42858 2/20 0.38
PKM P14618 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020805 0.91 ALDH1A1 (0.41) ALDH1A1LMNAPOLBKDM4EL3MBTL1
SCHEMBL1018353 0.90 ALDH1A1 (0.40) ALDH1A1LMNAPOLBL3MBTL1HTR7
SCHEMBL1019470 0.87 ALDH1A1 (0.50) GAAALDH1A1LMNAPOLBKDM4E
SCHEMBL1021548 0.86 ALDH1A1 (0.45) GAAALDH1A1LMNAPOLBTSHR
SCHEMBL1020985 0.85 ALDH1A1 (0.42) GAAALDH1A1POLBTSHRKDM4E
SCHEMBL1018475 0.84 ALDH1A1 (0.50) GAAALDH1A1LMNAPOLBHTR7
SCHEMBL1020806 0.83 GAA (0.47) GAAALDH1A1LMNAPOLBTSHR
SCHEMBL1020769 0.83 CYP19A1 (0.47) GAAALDH1A1LMNAPOLBL3MBTL1
SCHEMBL1021412 0.83 ALDH1A1 (0.51) GAAALDH1A1LMNATSHRL3MBTL1
SCHEMBL1020903 0.82 ALDH1A1 (0.49) GAAALDH1A1LMNAPOLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP GAA 205/4885ALDH1A1 608/4885LMNA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.